ORAL DOSES OF ABT-229 FOR POSTPRANDIAL DIGESTIVE SYMPTOMS/INSULI RQRNG DIABETES

口服 ABT-229 治疗餐后消化症状/INSULI RQRNG 糖尿病

• 批准号: 6276575
• 负责人: JAMES M GORDON
• 金额: $ 1.83万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276575
• 关键词: clinical research; dosage; drug screening /evaluation; gastrointestinal disorder chemotherapy; gastrointestinal hormones; gastrointestinal sign /symptom; human subject; human therapy evaluation; insulin dependent diabetes mellitus; macrolide antibiotics; oral administration; paralysis; pharmacokinetics; placebos; stomach

ABT-229 is a new drug that belongs to the class of macrolides with motilin agonist activity and without significant antibotic activity. Treatment of diabetic gastroparesis with motility agents have met with some success. ABT-229 has the potential to alter the pathophysiology and improve the symptoms in patients with diabetic gastroparesis without altering the normal gut flora. The objectives of this study are to assess the efficacy of four different doses of ABT-229 compared to placebo for the treatment of postprandial digestive symptoms and to assess the safety of ABT-229 in patients with insulin-requiring diabetes.

ABT-229是一种新的药物，属于大环内酯类药物。 有胃动素激动剂活性，没有明显的抗菌素活性。 运动药治疗糖尿病胃轻瘫的临床研究 取得了一些成功。ABT-229有可能改变其病理生理机制 并改善糖尿病胃轻瘫患者的症状 改变了正常的肠道菌群。这项研究的目的是 评估四种不同剂量ABT-229的疗效 安慰剂用于治疗餐后消化症状和 评价ABT-229在需要胰岛素的患者中的安全性 糖尿病。